At its 2026 Annual Meeting of Stockholders held on July 8, 2026, Traws Pharma, Inc. stockholders approved an amendment to the company's 2021 Incentive Compensation Plan to increase the available common stock for issuance by 2,000,000 shares. Additionally, shareholders approved the issuance of common stock upon the exercise of Series B and Series C Warrants issued to certain investors under an April 15, 2026, Securities Purchase Agreement, in compliance with Nasdaq listing rules. The meeting also resulted in the election of seven directors and the ratification of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year. Traws Pharma, Inc. is a pharmaceutical company.
